| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.39 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Parkinson’s disease (PD) is recognized as the second most prevalent primary chronic neurodegenerative disorder of the central nervous system. Clinically, PD is characterized as a movement disorder, exhibiting an incidence and mortality rate that is increasing faster than any other neurological condition. In recent years, there has been a growing interest concerning the role of the gut microbiota in the etiology and pathophysiology of PD. The establishment of a brain–gut microbiota axis is now real, with evidence denoting a bidirectional communication between the brain and the gut microbiota through metabolic, immune, neuronal, and endocrine mechanisms and pathways. Among these, the vagus nerve represents the most direct form of communication between the brain and the gut. Given the potential interactions between bacteria and drugs, it has been observed that the therapies for PD can have an impact on the composition of the microbiota. Therefore, in the scope of the present review, we will discuss the current understanding of gut microbiota on PD and whether this may be a new paradigm for treating this devastating disease.
Description
Keywords
Parkinson’s disease Microbiome Gut–brain axis
Citation
Vilela, C., Araújo, B., Soares-Guedes, C., Caridade-Silva, R., Martins-Macedo, J., Teixeira, C., Gomes, E. D., Prudêncio, C., Vieira, M., & Teixeira, F. G. (2024). From the gut to the brain: Is Microbiota a new paradigm in Parkinson’s disease teatment? Cells, 13(9), Artigo 9. https://doi.org/10.3390/cells13090770
Publisher
MDPI